David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Akamai
AKAM
$15.9B
| $57.2M | 0.07% |
797,706
-311,075
| -28% | -$21.1M |
|
|
327
CALL
PayPal
PYPL
$52.7B
| $57.1M | 0.07% |
549,600
+40,200
| +8% | +$3.81M |
|
328
East-West Bancorp
EWBC
$17.8B
| $56.9M | 0.07% |
1,185,485
+2,010
| +0.2% | +$103K |
|
329
Verizon
VZ
$205B
| $56.7M | 0.07% |
958,247
-82,208
| -8% | -$4.66M |
|
330
Twilio
TWLO
$34.6B
| $56.5M | 0.07% |
437,511
-659,033
| -60% | -$74.2M |
|
331
General Motors
GM
$77.2B
| $56.1M | 0.07% |
1,513,416
-963,187
| -39% | -$36.6M |
|
332
PUT
Walt Disney
DIS
$186B
| $56.1M | 0.07% |
505,300
-504,700
| -50% | -$56.4M |
|
333
CALL
Salesforce
CRM
$171B
| $56M | 0.07% |
353,500
+96,700
| +38% | +$15M |
|
334
RingCentral
RNG
$5.6B
| $55.9M | 0.07% |
518,899
-24,976
| -5% | -$2.45M |
|
335
PUT
Philip Morris
PM
$293B
| $55.8M | 0.07% |
630,800
+123,300
| +24% | +$9.93M |
|
|
336
PUT
Gilead Sciences
GILD
$181B
| $55.4M | 0.07% |
851,600
-390,800
| -31% | -$26M |
|
|
WBA
337
DELISTED
Walgreens Boots Alliance
WBA
| $55.2M | 0.07% |
873,132
-665,937
| -43% | -$45.5M |
|
338
PUT
AutoZone
AZO
$48.3B
| $55.1M | 0.07% |
53,800
-64,900
| -55% | -$58.3M |
|
339
Weyerhaeuser
WY
$17.6B
| $55.1M | 0.07% |
2,091,429
-1,757,640
| -46% | -$44.3M |
|
340
Goodyear
GT
$1.72B
| $55M | 0.07% |
3,028,076
+2,485,425
| +458% | +$48.4M |
|
341
General Dynamics
GD
$104B
| $54.6M | 0.07% |
322,789
+280,466
| +663% | +$47.3M |
|
|
342
Philip Morris
PM
$293B
| $54.6M | 0.07% |
617,558
-823,172
| -57% | -$66.3M |
|
343
PUT
Kraft Heinz
KHC
$30.3B
| $54.5M | 0.07% |
1,669,600
+1,235,000
| +284% | +$50.3M |
|
|
AGN
344
PUT
DELISTED
Allergan plc
AGN
| $54.5M | 0.07% |
372,100
-63,800
| -15% | -$9.25M |
|
345
Bloomin' Brands
BLMN
$996M
| $54.2M | 0.07% |
2,649,997
+483,084
| +22% | +$9.62M |
|
346
CALL
Home Depot
HD
$335B
| $54.1M | 0.07% |
281,900
+84,400
| +43% | +$15.5M |
|
347
Dentsply Sirona
XRAY
$2.18B
| $54M | 0.07% |
1,088,675
-833,124
| -43% | -$36.7M |
|
348
Armstrong World Industries
AWI
$7.55B
| $54M | 0.07% |
679,574
+54,522
| +9% | +$3.8M |
|
349
Northern Trust
NTRS
$33.6B
| $53.9M | 0.07% |
596,061
+111,441
| +23% | +$10M |
|
350
Cadence Design Systems
CDNS
$87.9B
| $53.7M | 0.07% |
846,075
-527,408
| -38% | -$27.9M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.